Origin Endoscopy Inc.
Publicly observedBaltimore, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Baltimore | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Origin Endoscopy Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | FNG7WGQLJ2U6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2026Publicly observed
NIH SBIR/STTR award: Development of EpiMAX, a first-in-class injectable hemostatic agent for long-acting hemostasis of gastrointestinal bleeding
USD 1,212,289.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.